Peptides identify multiple hotspots within the ligand binding domain of the TNF receptor 2

Proteome Science

Volumn 1, Issue , 2003, Pages

  Hsiao, Ku Chuan ^a   Brissette, Renee E ^a   Wang, Pinger ^a   Fletcher, Paul W ^a   Rodriguez, Vanessa ^a   Lennick, Michael ^a   Blume, Arthur J ^a   Goldstein, Neil I ^a  

^a DGI BioTechnologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; LIGAND; LYMPHOTOXIN; PEPTIDE LIBRARY; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

AMINO ACID SEQUENCE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN ISOLATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SEQUENCE HOMOLOGY;

EID: 0141503931     PISSN: 14775956     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-5956-1-1     Document Type: Article

References (40)

1. Starovasnik MA, Brasisted AC and Wells JA Structural mimicry of a native protein by a minimized binding domain. Proc Natl Acad Sci USA 1997, 94:10080-10085
2. Blume AJ, Beasley JR Jr and Goldstein NI The use of peptides in Diogenesis: a novel approach to drug discovery and phenomics. Biopolymers 2000, 55:347-356
3. Pillutla RC, Hsiao K-c, Beasley JR, Brandt J, Øtergaard S, Hansen PH, Spetzler JC, Danielsen GM, Andersen AS, Brissette RE, Lennick M, Fletcher PW, Blume AJ, Schaffer L and Goldstein NI Peptides identify the critical hotspots involved in the biological activation of the insulin receptor. J Biol Chem 2002, 277:22590-22594
4. Vassalli P The pathophysiology of tumor necrosis factors Ann Rev Immunol 1992, 10:411-452
5. Cope AP Regulation of autoimmunity by proinflammatory cytokines. Current Opinion Immunol 1998, 10:669-676
6. Liu J, Marino MW, Wong G, Grail D, Dunn A, Betadapura J, Slavin AJ, Old L and Bernard CC TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998, 4:78-83
7. Flynn J, Goldstein M, Chan J, Triebold K, Pfeffer K, Lowenstein C, Schreiber R, Mak T and Bloom B Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572
8. Heller R and Kronke M Tumor necrosis factor receptor-mediated signaling pathways J Cell Biol 1994, 126:5-9
9. Bazzoni F and Beutler B How do tumor necrosis factor receptors wor J Inflamm 1995, 45:221-238
10. Cope AP, Londei M, Chu N, Cohen S, Elliott M, Brennan F, Maini R and Feldmann M Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994, 94:749-760
11. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontigen F, Althage A, Zinkernagel R, Steinmetz M and Bluethmann H Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes Nature 1993, 364:798-802
12. Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O'Brien WA and Herbein G Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence. J Immunol 2000, 165:6437-46
13. Berkova N, Lemay A, Korobko V, Shingarova L, Sagaidak L and Goupil S Tumor necrosis factor mutants with selective cytotoxic activity. Cancer Detec Prev 1999, 23:1-7
14. Elsasser-Beile U, Kolble N, Grussenmeyer T, Wetterauer U and Schultze-Seemann W Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid. Anticancer Res 1998, 18(3B):1883-90
15. Lai N-S, Lan JL, Yu C-L and Lin R-H A dominant human leucocyte antigen DR4-Dw15 restricted mycobacterial 65 kDa antigen-specific T-cell immunity in Chinese patients with rheumatoid arthritis. Eur J Immunol 1995, 25:3243-3248
16. van Oosten B, Barkhof F, Truyen L, Boringa J, Bertelsmann F, von Blomberg B, Woody J, Hartung H and Polman C Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534
17. Bickston S and Cominelli F Treatment of Crohn's disease at the turn of the century. N Engl J Med 1998, 339:401-402
18. Lazdins J, Grell M, Walker M, Woods Cook K, Scheurich P and Pfizenmaier K Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. J Exp Med 1997, 185:81-90
19. Kusters S, Tieges S, Alexopoulou L, Pasparakis M, Douni E, Kunstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G and Grell M In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis Eur J Imunol 1997, 27:2870-2875
20. van Tits LJ, Bemelmans MH, Steinshamn S, Waage A, Leeuwenberg JF and Buurman WA Non-signaling functions of TNF-R75: findings in man and mouse. Circ Shock 1994, 44:40-44
21. Thoma B, Grell M, Pfizenmaier K and Scheurich P Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med 1990, 172:1019-1023
22. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G and Pfizenmaier K The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83:793-802
23. Grell M, Wajant H, Zimmermann G and Scheurich P The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor Proc Natl Acad Sci USA 1998, 95:570-575
24. Van Ostade X, Vandenabeele P, Everaerdt B, Loetscher H, Gentz R, Brockhaus M, Lesslauer W, Tavernier J, Brouckaert P and Fiers W Human TNF mutants with selective activity on the p55 receptor Nature 1993, 361:266-9
25. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nusslein H, Woody J, Kalden JR and Manger B In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996, 156:1646-1653
26. O'Dell JR Anticytokine therapy - a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999, 340:310-312
27. Kruppa G, Thoma B, Machleidt T, Wieqmann K and Kronke M Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the human 55-kDa TNF receptor. J Immunol 1992, 148:3152-3157
28. Carcamo J, Ravera MW, Brissette R, Dedova O, Beasley J, Alam-Moghe A, Wan C, Blume A and Mandecki W Unexpected frameshifts from gene to expressed protein in a phage-displayed peptide library. Proc Natl Acad Sci USA 1998, 95:11146-11151
29. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld H-J, Broger C, Loetscher H and Lessauer W Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation. Cell 1993, 73:431-445
30. Condorelli F, Sortino M, Stella A and Canonico P Relative contribution of different receptor subtypes in the response of neuroblastoma cells to tumor necrosis factor-alpha J Neurochem 2000, 75:1172-1179
31. Yanofsky SD, Baldwin DN, Bulter JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Whitehorn EA, Tate EH, Akeson A, Bowlin T, Dower WJ and Barrett RW High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA 1996, 93:7381-7386
32. Wrighton NC, Farrell FX, Chang R, Kashyup AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jollliffe LK and Dower WJ Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273:458-463
33. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK and Wilson IA Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996, 273:464-471
34. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, Schatz PJ, Baccanari DP, Wrighton NC, Barrett RW and Dower WJ Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997, 276:1696-1699
35. Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, Griffin P, Gao YD, Chapman K and Mark DF Mimicry of erythropoietin by a non-peptide molecule. Proc Natl Acad Sci USA 1999, 96:12156-12161
36. Tartaglia LA, Pennica D and Goeddel DV Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor J Biol Chem 1993, 268:18542-18548
37. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH and Lenardo DMJ Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377:348-351
38. Pillutla RC, Hsiao K-c, Brissette R, Eder PS, Giordano T, Fletcher PW, Lennick M, Blume AJ and Goldstein NI A surrogate-based approach for post-genomic partner identification. BMC Biotechnol 2001, 1:6-14
39. Slack J, Sims JE, Pitt AM and Dower SK Application of the Multi-Screen system to cytokine radioreceptor assays BioTechniques 1998, 7:1132-1138
40. Cheng Y and Prusoff WH Mouse ascites sarcoma 180 thymidylate kinase. General properties, kinetic analysis, and inhibition studies Biochem Pharmacol 1973, 22:3099-3108